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Objective: To determine the role of anti-Mullerian hormone (AMH) levels in predicting the response to
clomiphene citrate (CC) therapy for ovulation induction in women with unexplained infertility.
Materials and methods: For this retrospective study, fifty consecutive patients who responded to CC were
taken as Group 1, while fifty consecutive patients who failed to show adequate ovulatory response with
CC were taken as Group 2. We compared the AMH levels of the two groups and receiver operating
characteristic (ROC) curve was used to determine the threshold for AMH in predicting the ovulatory
response to CC therapy.
Results: Mean age, body mass index, luteinizing hormone, prolactin, and thyroid-stimulating hormone
values were similar in the two groups. AMH and antral follicle count (AFC) values were higher in Group 1
than in Group 2 (p ¼ 0.001 and p ¼ 0.001, respectively). There was a statistically significant negative
correlation between FSH and AFC (r ¼ 0.339, p ¼ 0.001), while AFC and AMH displayed a statistically
significant positive correlation (r ¼ 0.713 and p ¼ 0.001). AMH values and AFC were found to be pre-
dictors of the adequate ovulatory response to CC. The area under the ROC curve was 0.86 vs 0.80,
respectively. At an AFC cutoff value of 14, the sensitivity and specificity for prediction of ovulation were
68% and 80%, respectively.
Conclusion: The AMH and AFC cut-off values for the prediction of positive ovarian response to CC in
patients with unexplained infertility were 2.78 ng/mL and 14, respectively. If further prospective and
randomized studies confirm our results, these thresholds may be useful to predict successful ovulation
induction and reduce the unresponsive cycles.
© 2018 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Infertility and its associated problems are known to affect 15% of
couples [1]. Anovulation, tubo-peritoneal factors and male infer-
tility are the main causes of infertility. Among infertility patients nostetrics and Gynecology, Etlik
ching and Research Hospital,
ning and Research Hospital,
ar Sinan Mah. Emniyet Cad.,
kkurt).
Gynecology. Publishing services b
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. No other uses without permission. Ccausative factor can be detected with a rate of 16e20% when cur-
rent infertility work-out is used and these patients are classified as
unexplained infertility [2]. Ovulation induction followed by intra-
uterine insemination is usually the first-line treatment in patients
with unexplained infertility. Clomiphene citrate (CC) has been used
as the first-line agent for ovulation induction [3]. The empiric use of
clomiphene citrate with or without intrauterine insemination in
womenwith unexplained infertility was proposed for correction of
the subtle ovulatory dysfunction and/or ovulation of more than 1
oocyte [4]. In comparison to superovulationwith gonadotropins, CC
has fewer side effects, lower cost, and acceptable success rates [5].
During the last decade, the importance of anti-Mullerian hor-
mone (AMH) in the assessment of the ovarian reserve has becomey Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
niversitesi from ClinicalKey.com by Elsevier on April 18, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Table 1
Comparison of demographic and laboratory features of study population.
Group 1 (n ¼ 50)
(responders)
Group 2 (n ¼ 50)
(non-responders)
p-value
Age (year) 26.3 ± 4.7 27.9 ± 3.6 0.063
BMI (kg/m2) 24.8 ± 2.4 24.4 ± 2.7 0.489
FSH (IU/I) 6.1 ± 1.2 6.8 ± 1.4 0.005
LH (U/I) 5.3 ± 2.1 6.2 ± 2.5 0.096
Estradiol (pg/ml) 33.7 ± 13.6 42,6 ± 15.4 0.003
TSH (mIU/I) 1.90 ± 0.77 1,98 ± 0.81 0.694
Prolactin (ng/ml) 12.4 ± 5.0 14.4 ± 5.5 0.063
AMH (ng/ml) 3.01 ± 0.52 2.23 ± 0.50 0.001
AFC 15.2 ± 1.6 13.1 ± 1.8 0.001
Data are given as mean ± standard deviations. Body mass index (BMI); follicle
stimulating hormone (FSH); luteinizing hormone (LH); thyroid stimulating hor-
mone (TSH); anti-Mullerian hormone (AMH); antral follicle count (AFC).
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growth factor family is secreted to the blood stream after its pro-
duction from the granulosa cells of the pre-antral and antral follicles.
AMH concentrations reflect the quantity of follicular pool and thus is
used as a sensitive marker of the ovarian reserve. The value of AMH
in prediction of ovarian response in gonadotropin stimulated cycles
has been studied at the beginning of last decade. Seifer et al. found a
relationship between early follicular phase serum AMH levels and
the number of oocytes developed during ovulation induction [7]. The
number of oocytes collected was particularly high in the presence of
high serum AMH levels, leading to a higher yield of mature oocytes.
The serum AMH level was found to be valuable in prediction of the
number of oocytes collected at controlled hyperstimulation during
in vitro fertilization (IVF) cycles [7].
In this study, in addition to previous studies that focused on the
predictive value of AMH in gonadotropin induced ovulation in-
duction cycles, we investigated the value of AMH levels in pre-
dicting the response to CC administration in patients with
unexplained infertility and analyzed the correlation between antral
follicle count (AFC) and serum AMH, a cycle day 3 follicle stimu-
lating hormone (D-3 FSH) and estradiol (E2) levels.
Material and method
This retrospective study included 100 patients who were
admitted to Ministry of Health Etlik Zubeyde Hanim Woman's
Health Teaching and Research Hospital. All patients were diagnosed
with unexplained infertility after routine infertility assessment and
were scheduled for ovulation induction using CC followed by in-
trauterine insemination. This studywas approved of by local ethical
committee, Education Planning Committee. The study is a retro-
spective study and the investigators aimed to recruit participants to
both the study and the control group from the computarized re-
cords of the patients who were scheduled for their first CC þ IUI
cycle at the “Reproductive Endocrinology Outpatient Clinic” of the
hospital between the given dates (JanuaryeDecember 2015). From
the first day of the initiation of the study, patients with unexplained
infertility who met the inclusion criteria but did not have the
exclusion criteria from both the responders (N:50) and non-
responders (N:50) were included. We recruited 50 consecutive
patients for each group. No patients were skipped in order to avoid
the bias. The recruitment process was completed after reaching the
targeted number for each group. The inclusion and exclusion
criteria were strictly followed-up. After analyzing the patient re-
cords, patients who did not meet the inclusion criteria [being <36
years of age, failing to become pregnant despite regular sexual in-
tercourse for 1 year without any contraceptive use, having regular
menstrual cycles, ovulation confirmed by mid-luteal progesterone
(serum progesterone level >3 ng/dl) measurement, with pat-
ent uterine tubes on hysterosalpingography, and a basal FSH
<10 IU/mL.] or had one or more of the exclusion criteria [patients
who had polycystic ovarian disease, endocrinological problems,
chronic diseases, myomas, endometriosis, previous history of pelvic
surgery or male infertility with 2 abnormal male semen analysis
according to the World Health Organization (WHO) criteria [8]]
were not included to the study. No other factors played a role in the
selection process. All the patients had their first treatment cycle.
They were put on to CC (Klomen 50 mg, Kocak Farma, Turkey) for
ovarian stimulation, and the treatment was started on day 3 of
menstrual cycle with a dose of 50 mg twice daily for 5 days. The
patients had daily ultrasonographic examination and 10,000 U hCG
(Pregnyl 5000 IU/amp. 1  2, im, Organon, Turkey) was adminis-
tered to trigger ovulation when at least one follicle was observed
to exceed a diameter of 18 mm. IUI was performed 36 h after hCG
administration.Downloaded for Anonymous User (n/a) at ULAKBIM Academic  Baske
For personal use only. No other uses without permissionOn the morning of day 3 of the treatment cycle, 8 mL of venous
blood was collected from cubital vein, the samples were centri-
fuged at 3500 rpm and blood serum was refrigerated at 20 C.
Quantitative serum FSH, TSH, LH, E2 and Prolactin measurements
were done by using the chemiluminescent microparticle immu-
noassay (CMIA) method (Abbott Laboratories, Illinois, USA), while
quantitative AMH measurements were carried out using the
enzyme-linked immunosorbent assay (ELISA) method (Diagnostic
Systems Laboratories, Webster, Texas, USA).
Baseline transvaginal ultrasonography (USG) in the early follic-
ular phase was performed before treatment to measure the sizes of
the uterus and ovaries, as well as the number and diameter of
follicles. The AFC was defined as the total number of follicles with a
diameter of 2e10 mm in both ovaries on day 3 before the ovarian
stimulation. Baseline TVUSG assessment and follicle development
was followed up by using a General Electric Logiq P5 Ultrasound
(6.5 MHz microconvex) vaginal probe. The patients were followed
until the 21st day, and the patients who developed at least one
follicle of >16 mm in diameter were considered as a positive
ovarian response and had intrauterine insemination 36 h after re-
combinant hCG administration (Ovitrelle 250mcgMerck) (Group 1,
n ¼ 50). The patients who failed to develop at least a follicule
<16 mm in diameter were taken as the nonresponsive group
(Group 2, n ¼ 50). AMH levels were compared between the two
groups and the value of the AMH level in predicting the outcome of
CC therapy was calculated. Moreover, in both groups, the correla-
tion between the AMH level and body mass index (BMI), basal
serum FSH, LH, estradiol (E2), thyroid-stimulating hormone (TSH),
prolactin levels, and antral follicle count (AFC) were evaluated.
The sample size of the study was calculated with G*Power
(G*Power Ver. 3.1.9.2, Franz Faul, Üniversit€at Kiel, Germany) sta-
tistical packages. The required sample size for 88% power, a ¼ 0.05
Type I error, b ¼ 0.20 Type II error and f ¼ 0.70 effect size was
calculated as 26 for each group. The study data was analyzed with
SPSS version 17 using definitive statistics, the Student's t-test, the
ManneWhitney U test, Pearson correlation analysis, the analysis of
variance (ANOVA) test, Bonferroni correction, and receiver oper-
ating characteristic (ROC) curve analysis. P-value < 0.05 was
considered as statistically significant.Results
The demographic and laboratory features of both groups were
shown in Table 1. Both groups had similar mean age, BMI, serum LH,
prolactin, and TSH values (p > 0.05). Serum AMH values and AFC
were significantly higher in Group 1 than in Group 2 (p¼ 0.001 and
p¼ 0.001, respectively). Serum FSH and E2 values were significantlynt Universitesi from ClinicalKey.com by Elsevier on April 18, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
Fig. 1. ROC curve of AMH and AFC values according to response to clomiphene citrate.
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respectively).
The ROC curve was drawn for the AMH and AFC levels by
calculating sensitivity and specificity of AMH and AFC in showing
the CC response. At an AMH cutoff value of 2.78 ng/mL, the sensi-
tivity and specificity to CC responsewere 74% and 86%, respectively.
The sensitivity and specificity of AMH measured for other values
are shown in Table 2. At an AFC cutoff value of 14, the sensitivity
and specificity were 68% and 80%, respectively. The ROC curve is
shown in Fig. 1. AMH and AFC values were found to be significantly
valuable in predicting response to CC. The area under the curve
(AUC) was 0.862 for AMH, while it was 0.792 for AFC. In this study,
AMH had a higher area under the ROC curve than AFC. Therefore,
AMH was more effective in predicting the response to CC. The AUC
and statistical significance values for AMH and AFC are shown in
Table 3.
Moreover, in both groups, the correlation of the serum AMH
levels with age, basal serum FSH levels, and antral follicle count
(AFC) were evaluated. On the other hand, there was a significant
negative correlation between D-3 serum FSH and AFC (r ¼ 0,339,
p ¼ 0,001); while there was a significant positive correlation be-
tween the AFC and serum AMH levels (r ¼ 0.713, p ¼ 0.001)
(Table 4). Table 4 shows pairwise comparisons of each parameter
(FSH, AFC, AMH and age) with correlation coefficient (r) and sig-
nificance value (p).
The ANCOVA (analysis of covariance) showed that serum AMH
levels alone had statistically significant value in predicting ovula-
tory response to CC (p ¼ 0.001).Discussion
A cause for a subtle ovulatory disfunction was investigated in
patients with unexplained infertility, however an abnormality in
pulastile GnRH secretion or sensitivity to GnRh was not shown in
the early studies [9]. Hormonal monitoring and measurement of
physiological response to GnRh in women with unexplained
infertility pointed out “diminished ovarian reserve” as a possible
cause of unexplained imfertility [9,10]. Ekka et al. reported lower
AMH values in women with unexplained infertility on comparison
to age-matched fertile women [11]. AMH levels were evaluated in
patients with unexplained infertility who were followed-up for 5
years as a predictor for future live birth and a cut of value of
10 pmol/L in combination with age and presence of ovulatory
cycles was found to have high predictive value [12]. However
Casadei et al. reported that AMH did not have a predictive value in
predicting spontaneous pregnancy in patients with unexplained
infertility [13]. Satwick et al. reported a more absolute cut-off level
of 2 pmol/L (98% specificity, 20% sensitivity) for prediction of
negative ovarian response while the AMH levels had a huge vari-
ation between 2 and 10 pmol/L in average responders in patients
who underwent IVF-ET cycles [14]. Rigon et al. reported an asso-
ciation between normo-ovulatory infertility and AMH and AMH
receptor type II (AMHRII) polymorphisms that might be speculatedTable 2
Sensitivity and specificity rates for AMH levels in response to clomiphene citrate.
Anti-Mullerian hormone (ng/ml) Sensitivity Specificity
2.72 0.76 0.80
2.75 0.76 0.84
2.78 0.74 0.86
2.80 0.72 0.86
2.82 0.72 0.88
A maternal serum anti-mullerian cut-off 2.78 ng/ml was found to be optimal for
determination of response to CC with a sensitivity of 74% and specificity of %86.
Downloaded for Anonymous User (n/a) at ULAKBIM Academic  Baskent U
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and reproductive outcome in some patients [15].
Ovulation induction or augmentation is with or without IUI,
gonadotropins and IVF is used for treatment of women with un-
explained infertility [16]. Despite advances in the assisted repro-
ductive technologies, there is an ongoing discussion on diagnostic
tests that predict poor ovarian respond for each treatment modality
[17]. Fanchin investigated the correlation between serum AMH;
FSH; LH; E2, inhibin B levels of 75 infertile women and the early
AFC performed on cycle Day 3. While only AMH, inhibin B and FSH
were significantly correleted with early AFC, the strongest corre-
lation was between AMH and early AFC (r ¼ 0.74, P < 0.0001) [18].
In the presented study, in women with unexplained infertility D-3
FSH and AFC values had a statistically significant negative correla-
tion (r ¼ 0.339, p ¼ 0.001); while AFC and AMH values had a
statistically significant positive correlation (r ¼ 0.713, p ¼ 0.001).
A previous study from Turkey demonstrated that in 180 patients
who had their first IVF cycle a cut-off value of 2.97 ng/mL for AMH
was found to predict the poor ovarian response with a sensitivity of
100.0% and a specificity of 89.6 [19]. Lee et al. reported a cut-off
value of 1.05 ng/mL for nonpregnancy and 0.68 ng/mL for cycle
cancellation in 116 infertile patients 40 years of age who had IVF/
ICSI [20]. In 90 womenwho had their first IVF/ICSI cycle, a baseline
Day-3 serum AMH level below 2.74 ng/mL had a sensitivity of 69%
and specificity of 70.5% in prediction of poor ovarian response [21].
Sahmay et al. used FSH, E2, and AMH levels in addition to AFC on
day 3 of the menstrual cycle in order to predict ovarian response to
COH treatment and reported that AMH was significantly more
successful in predicting the response in comparison to serum FSH,
E2 levels and AFC. They reported that an AMH cutoff value of 2
(ng/mL) predicted poor response with a sensitivity and a specificity
of 78.9% and 73.8% respectively [22]. Nardo et al. investigated the
role of AMH in prediction of response to ovarian hyperstimulationTable 3
Statistical significance values and AUC of the AMH and AFC.
Cut-off ROC AUC 95% CI p-value Sensitivity Specificity
AMH
(ng/ml)
2.78 0.862 0.791e0.933 0.001 74% 86%
AFC 14 0.792 0.711e0.883 0.001 68% 80%
AMH, anti-Mullerian hormone; AFC, antral follicle count; ROC AUC, receiving
operator curve area under curve.
niversitesi from ClinicalKey.com by Elsevier on April 18, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Table 4
The correlation coefficients and significant values between the FSH, AFC, AMH and
age of the patients.
AFC AMH (ng/ml) Age (year)
FSH (IU/I) r 0.339 0.551 0.138
p 0.001 0.001 0.172
AFC r 0.713 0.279
p 0.001 0.005
AMH (ng/ml) r 0.331
p 0.001
FSH, follicle stimulating hormone; AFC, antral follicle count; AMH, anti-Mullerian
hormone; r, correlation coefficient; p < 0.05 statistically significant.
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88% sensitivity and 70% specificity at an AMH cut-off value of >3.5,
while poor response was predicted by 87% sensitivity and 67%
specificity with a cut-off value of <1 [23]. In the presented study, in
CC cycles the cut-off value for AMH was found to be 2.78 ng/mL for
prediction of poor ovarian response with a sensitivity and speci-
ficity of 74% and 86%, respectively. The presented cut-off value
obtained in CC cycles was compatible with the studies in the
literature although gonadotropins were used for ovulation induc-
tion in these studies [19,21].
The predictive value of AFC in ovarian response have been
subject to various studies. In the presented study an AFC cutoff
value of 14 was found to be predictive of ovarian response with a
sensitivity and specificity of 68% and 80%, respectively. Adibi et al.
reported a cutoff value of 15.5 for predicting ovarian responsiveness
in clomiphene citrate cycles and stated that AFC had a better pre-
dictive value than ovarian volume and hormonal tests [24]. In a
study that aimed to determine the basal value of AFC in subfertile
and fertile Indian population a large percentage (86.7%) of the
fertile populationwas found to have an AFC > 10 [25]. The AFC level
was statistically significantly lower in the non-responsive group
(13.1 ± 1.8 vs 15.2 ± 1.6, p ¼ 0.001).
Eldar-Geva et al. analyzed AFC, serum inhibin-B, AMH, and FSH
levels in 56 women going under COH with recombinant FSH. They
showed that while AFC, follicular AMH and induced inhibin B levels
had a predictive value for poor ovarian response only serum AMH
(either follicular or luteal) had a predictive value in achieving
pregnancy; a cut-off basal AMH (either follicular or luteal) of
2.52 ng/mL had a positive predictive value of 67% and a negative
predictive value of 61% for achieving an ongoing pregnancy
(p < 0.01) [26]. Hazout et al. found a strong relationship between
basal serum AMH levels and the number of mature oocytes, em-
bryos and even clinical pregnancy rates. In 109 IVF patients under
42 years of age, women who became pregnant had a mean serum
AMH value of 2.4 ng/mL (38 patients) and while this was 1.1 ng/mL
in nonpregnant women (71 patients) [27].
In the literature, studies investigating the efficacy of serumAMH
level in prediction of ovarian response to CC have been conducted
only in infertile women with polycystic ovary syndrome [28e30].
Mahran et al. reported a significantly lower serum AMH level in 187
PCOS patients who were responsive to CC (AMH levels for the
responsive and nonresponsive groups were 2.5 ± 0.1, 5.8 ± 0.7,
respectively, p < 0.001) [28]. Ellakwa et al. and Xi et al. also stated
that serum AMH levels might be useful in prediction of ovarian
response to clomiphene citrate in patients with PCOS [31,32].
The underlying reason of the negative correlation between
serumAMH levels and response to ovulation inductionwith CCwas
associated with increasing serum AMH levels in relation to growing
number of ovarian preantral and small antral follicles in polycystic
ovary syndrome in response to CC [32]. This is thought to be related
to be the inhibitory effect of AMH on FSH-stimulated follicle growth
and eventually this will alter the follicular growth by decreasingDownloaded for Anonymous User (n/a) at ULAKBIM Academic  Baske
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studies in the literature, the patients diagnosed with PCOSwere not
included. In this study normoovulatory patients with unexplained
infertility received ovulation inductionwith CC and both the serum
AMH levels and AFC values were found to be significantly higher in
responders, while serum FSH and E2 in the same group.
In conclusion, despite the well-recognized association between
AMH and the ovarian reserve, the correlation between serum AMH
levels and response to ovulation induction with CC in patients
unexplained infertility needs further investigation In the presented
study, a serum AMH cut-off value of 2.78 ng/mL was found to be
optimal for predicting the response to CC treatment for ovulation
induction in patients with unexplained fertility andwe recommend
using gonadotropin for ovulation induction at values below this
cut-off value. Routine serum AMH level measurement may be
useful for individualization of treatment modality in unexplained
infertility patients. However, due to a limited number of patients
recruited to the study, further prospective and randomized studies
with larger patient groups are required.
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